top of page

Pere Santamaria, M.D., Ph.D

Praespero - An Autoimmune Research Fund LOGO 10_rEVERSE.png

Pere Santamaria, M.D., Ph.D.

Scientific Advisory Board Member, Praespero Professor, Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary


Key Achievements

  • Founder of Parvus Therapeutics, which developed Navacim™ nanomedicines for autoimmune disease

  • Parvus entered a 2017 licensing agreement with Novartis to advance clinical development and commercialization

  • Authored more than 190 publications, holds 92 patents, and has delivered more than 250 lectures

  • Winner of the 2013 ASTech Award for Outstanding Leadership in Alberta Technology

  • Brings both extraordinary scientific achievement and lived experience with autoimmune disease to Praespero's Scientific Advisory Board.


ABOUT 


For more than 20 years, Pere Santamaria has worked to understand and treat autoimmune disease, with a particular focus on type 1 diabetes. His commitment is deeply personal. 


At 15, he spent most of a year in the hospital before being diagnosed with myasthenia gravis, an autoimmune condition that disrupts communication between nerves and muscles. He went on to earn his M.D. and Ph.D. at the University of Barcelona, then completed postdoctoral research at the University of Minnesota. Recognizing how little research was devoted to type 1 diabetes, he accepted a position at the University of Calgary to lead his own team and study it.


Dr. Santamaria's work led to a new therapeutic platform based on nanomedicine. Navacim™ nanoparticles are coated with disease-relevant proteins that bind specifically to the T cells attacking the body's own tissue. Rather than suppressing the whole immune system, they reprogram these cells, which stop their attack and instead multiply into regulatory networks that protect the affected tissue. This precision approach has shown it can suppress several autoimmune disorders in preclinical models without compromising systemic immunity, offering a path toward reversing disease rather than merely managing symptoms. His team's current research focuses on how these regulatory networks form and are sustained, and on selecting candidate therapies using mice humanized with patient immune cells.


Beyond the lab, Dr. Santamaria has translated discovery into real-world impact. Through Parvus Therapeutics, and its partnership with Novartis, his work is moving toward clinical development, bringing the field closer to what could be the first cure for type 1 diabetes. On Praespero's Scientific Advisory Board, he brings the pioneering, boundary-pushing thinking that Praespero exists to support.

bottom of page